Sentences with phrase «ovarian tumors in»

Granulosa cell and epithelial tumors are the most common ovarian tumors in bitches.

Human Warnings: Carcinogenesis: Nitrofurazone has been shown to produce mammary tumors in rats and ovarian tumors in mice.

As proof - of - principle of the potential efficacy, Zhang's team grew human ovarian tumors in immunocompromised mice, then injected short - interfering RNAs to block the tumors» growth using RNA interference against FAL1.

I have an ovarian tumor in my remaining ovary (other ovary remove 4 years ago due to same cause).

Not exact matches

Additional clinical trial data later this year on Tesaro's key drug, Niraparib, which targets advanced solid tumors in ovarian and breast cancers, could help narrow the valuation gap, the people said.

(A BRCA1 mutation predisposes a woman to either breast or ovarian tumors, in some cases both.)

Seventy four percent of enrolled patients were diagnosed with ovarian cancer with tumors that had relapsed and metastasized in the peritoneum, the membrane that lines the abdominal cavity.

Shih, Wang and their colleagues tested fostamatinib's power to reduce tumor size in mice implanted with human ovarian cancer cells that were resistant to paclitaxel.

Moreover, experiments on an ovarian cancer murine model that investigated the effects of orally administered ONA resulted in longer lifespans and inhibited ovarian cancer tumor development.

«In pancreatic, ovarian and liver cancers, we hope that by adding anti-cancer stem cell drugs to standard of care, we can control proliferating cells within the tumor that could otherwise help the tumor regenerate in the face of existing chemotherapies.&raquIn pancreatic, ovarian and liver cancers, we hope that by adding anti-cancer stem cell drugs to standard of care, we can control proliferating cells within the tumor that could otherwise help the tumor regenerate in the face of existing chemotherapies.&raquin the face of existing chemotherapies.»

«This finding,» Villanueva said «opens the door to developing new biomarkers and new therapeutic strategies exploiting these characteristics of exosomes in breast tumors, and other tumors such as ovarian and endometrial cancer among others.»

In an earlier Penn Medicine study, 38 percent of all patients (and 46 percent of females with the condition) were found to have a tumor, most commonly it was an ovarian tumor.

The study published in Cancer Cell shows that exosomes from tumor cells of breast cancer (and other tumor types such as ovarian and endometrial) are different in size and composition than those of healthy cells.

«Personalized tumor vaccine shows promise in pilot trial: Vaccine against patients» own tumors triggers a broad response, and induced five - year remission in one patient with advanced ovarian cancer.»

Razqallah Hakem, a cancer biologist at the University of Toronto in Ontario, and his colleagues normally study a tumor suppressor called BRCA1, variants of which put women at high risk of breast and ovarian cancer.

«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.

The researchers found that these immune system pathways were suppressed in a large number of primary tumors — roughly 50 percent of ovarian cancers studied, 40 percent of colorectal cancers and 30 percent of breast cancers.

The team's recent study in mice has found that the treatment reduced the mass of ovarian cancer tumors and was more effective at suppressing tumor growth than chemotherapy.

Heeke says the study would be open to people whose tumors have evidence of HRD like those found in this study, which includes bladder, breast, cervix, liver and bile duct, colorectal, endometrial, gastric / esophageal, head & neck, kidney, neuroendocrine, lung, ovarian, pancreas, prostate, sarcoma, and thyroid cancers, as well as gastrointestinal stromal tumors, glioma, melanoma and unknown primary cancers.

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur.

When COXEN looked back through this registry of advanced ovarian cancer, it first sorted tumors into those that had responded and those that had not responded to each drug («what would have been the right drug in each case»).

The lab of co-author Dr. Robert Bast Jr., an expert in ovarian cancer and vice president for translational research at MD Anderson, inserted gel - bound carbon nanotubes into the ovaries of rodents to mimic the accumulations that are expected for nanotubes linked to special antibodies that recognize tumor cells.

P: We found discodermolide [a drug from Discodermia, a sponge found in the Caribbean, the Bahamas, and the Gulf of Mexico], and it's gone through phase I clinical trials for treatment of solid tumors such as ovarian, pancreatic, breast, colon, or lung cancers.

Scientists identified the specific proteins secreted by the parasite Toxoplasma gondii that cause the immune system in mice to attack established ovarian tumors.

«STAT3 is the primary marker that is used today to ascertain malignancy, tumor aggression and metastasis in ovarian cancer.»

A section of a tumor organoid grown from cells derived from a patient with high - grade serous ovarian cancer (left) and a mini-tumor treated with ReACp53, resulting in extensive cancer cell death.

But mutations, which are found in 96 percent of patients with high - grade serous ovarian tumors, can cause p53 to form clumps, or «aggregates,» which impair the protein's normal function.

In some cases such as ovarian cancer, however, drug - free intervals are needed to allow patient recovery from side effects, during which tumors can sometimes begin to grow again or develop resistance to the drugs being used.

Furthermore, higher levels of LAPTM4B, a gene that has been found in liver, lung, breast, ovarian and gastric cancers, were found in airways closer to tumors.

She estimates that about 50 percent of women with ovarian cancer have tumors with this type of tumor and would qualify for the trial, which needs about $ 2 million in philanthropic funding before it could begin.

Now, MIT engineers have developed a far more sensitive way to reveal ovarian tumors: In tests in mice, they were able to detect tumors composed of nodules smaller than 2 millimeters in diameteIn tests in mice, they were able to detect tumors composed of nodules smaller than 2 millimeters in diametein mice, they were able to detect tumors composed of nodules smaller than 2 millimeters in diametein diameter.

In humans, colon cancer often spreads to the liver and forms small tumors that are difficult to detect, similar to ovarian tumors.

«We expect that the proposed treatment will be especially effective in advanced stages of ovarian cancers, where there are many cancer stem cells in the tumors that resist conventional drug treatment,» says Minko.

In their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors found in women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratory micIn their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors found in women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratory micin women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratory mice.

Now, results of a study of nine women suggest that the genomic roots of many ovarian tumors may indeed arise in the fallopian tubes, potentially providing insights into the origin of ovarian cancer and suggesting new ways for prevention and intervention of this disease.

A newly devised tumor - specific fluorescent agent and imaging system guided surgeons in real time to remove additional tumors in ovarian cancer patients that were not visible without fluorescence or could not be felt during surgery, reports Alexander L. Vahrmeijer MD, PhD, head of the Image - guided Surgery group in the Department of Surgery at Leiden University Medical Center in the Netherlands.

By combining these two refinements, the researchers were able to enhance the sensitivity of the sensor 15-fold, which they showed was enough to detect ovarian cancer composed of small tumors (2 millimeters in diameter) in mice.

In a major breakthrough for ovarian and uterine cancers, Yale researchers have defined the genetic landscape of rare, highly aggressive tumors called carcinosarcomas (CSs), pointing the way to possible new treatments.

Surgeons gathered to focus on a quality improvement program to address a central issue in treating advanced ovarian cancer — how to optimize surgery to achieve complete removal of all visible tumor — also called optimal resection.

Since SFRP2 is expressed in many cancers — including breast, colon, pancreas, ovarian and kidney tumors — the technique could potentially be useful on a broad range of cancer types.

While previous research had shown some effectiveness of this molecule in a mouse model of ovarian cancer, that benefit was limited by the immunosuppressive environment within tumors, particularly the presence of regulatory T cells (Tregs).

VIC - 008 is a fusion protein combining an immune - activating protein from the tuberculosis bacteria with a small antibody fragment targeting mesothelin, a protein expressed in several types of tumor — including mesothelioma, pancreatic and ovarian cancer.

But so far in trials for ovarian cancer they have blocked tumor growth in many patients, Levine notes.

Led by Ludwig Lausanne investigator Alexandre Harari and George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne, the study shows that ovarian tumors harbor highly reactive killer T cells — which kill infected and cancerous cells — and demonstrates how they can be identified and selectively grown for use in personalized, cell - based immunotherapies.

Women with Stage III ovarian cancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone, according to a study published conducted by the Gynecologic Oncology Group (GOG), a National Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of Medicine.

The 3 ovarian cancer cases diagnosed before age 18 years were germ cell tumors and included in the analysis (Table 1).

Next they treated the experimental tumor cells with MIR506 to determine if it would behave in the same way it had with ovarian and other cancers.

[4] Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell - McGuinn K, Hensley ML, Konner J, Tew W, Spriggs DR, Hoffman EW, Venhaus R, Pan L, Salazar AM, Diefenbach CM, Old LJ, Gnjatic S. Phase I trial of overlapping long peptides from a tumor self - antigen and poly - ICLC shows rapid induction of integrated immune response in ovarian cancer patients.

In their most intriguing work, they're collaborating on something new: a «theranostic» nanoparticle that can both diagnose and attack ovarian tumors.

The earliest and one of the most striking came from observations that the presence of infiltrating T cells (called «tumor - infiltrating lymphocytes,» or TILs) in ovarian tumors is positively and strongly associated with improved survival of patients with ovarian cancer [1].